Background: Axillary Brachial plexus block is the distal block performed on the brachial plexus. With the advent of ultrasound guidance establishing the blockade has been easier with reduced drug dosage and less complications. Objective: To evaluate and compare the effects of addition of clonidine with ropivacaine for axillary block with reference to a) onset of sensory blockade b) onset of motor blockade c) duration of analgesia. Methods: 60 patients of ASA class 1& 2 for upper limb surgical procedures were randomly allocated into two groups of 30 each, Group P will receive ropivacaine 0.75% 20ml + NaCl 0.9% (0.5ml) Group D will receive ropivacaine 0.75% 20ml + clonidine 75µg (0.5ml). With ultrasound guidance axillary brachial plexus block was administered. Testing for onset of sensory blockade was done using pin prick method, Motor block was assessed using modified Bromage scale, Post operatively patients would be assessed for the duration of sensory and motor blockade. Results: The present study shows that 20 ml of 0.75% Ropivacaine with clonidine 75 mcg prolonged the duration of motor, sensory block and duration of analgesia when compared with 20 ml of 0.75% Ropivacaine with NaCl 0.9% .The onset of sensory, motor blocks was significantly faster with 0.75% Ropivacaine with clonidine 75 mcg group (Group D) when compared with 0.75% Ropivacaine with NaCl 0.9% group (Group P). Conclusion: Clonidine 75 µg as an adjuvant to 0.75% ropivacaine produces satisfactory onset of sensory and motor blockade, with increased duration of analgesia when used for axillary brachial plexus block under ultrasound guidance without any adverse effects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.